#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Colorectal cancer − the importance of primary tumor location


Authors: M. Ryska 1,3;  J. Bauer 2
Authors‘ workplace: Chirurgická klinika 2. LF Univerzity Karlovy a ÚVN, Praha přednosta: prof. MUDr. M. Ryska, CSc. 1;  emeritní docent 1. LF Univerzity Karlovy 2;  Fakulta zdravotníctva a sociálnej práce, Trnavská Univerzita, Trnava děkan: prof. MUDr. J. Slaný, CSc. 3
Published in: Rozhl. Chir., 2017, roč. 96, č. 1, s. 4-8.
Category: Review

Overview

Retrospective evaluations of the relevance of primary colorectal cancer (CRC) location consistently indicate that right-sided tumors, arising in the cecum, ascending colon, hepatic bend, transverse colon and splenic flexure, are clinically, biologically and genetically different from left-sided tumors – those located in the descending colon, sigmoid colon or rectum. Location in the right-sided colon represents a negative prognostic indicator, particularly for stage III and IV carcinomas. Irrespective of treatment, the rightward location is associated with a significantly increased risk of death when compared to the left side.

Key words:
colorectal cancer – location – therapy - prognosis


Sources

1. Nová data Národního onkologického registru (NOR) za rok 2014. NZIS Report č. R/1 (09/2016); www.uzis.cz

2. Suttie SA, Shaikh I, Mullen R, et al. Outcome of right- and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis 2011;13:884−9.

3. Park IJ, Choi GS, Kang BM, et al. Lymph node metastasis patterns in right-sided colon cancers: is segmental resection of these tumors oncologically safe? Ann Surg Oncol 2009;16:1501−6.

4. Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol 2015;21:6470−8.

5. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426−32.

6. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545−50.

7. Glockzin G, Schlitt HJ, Piso P. Therapeutic options for peritoneal metastasis arising from colorectal cancer. World J Gastrointest Pharmacol Ther 2016;7:343−52.

8. Huang CW, Tsai HL, Huang MY, et al. Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer. World Journal of Surgical Oncology 2015;13:257.

9. Ishihara S, Nishikawa T, Tanaka T, et al. Prognostic impact of tumor location in stage IV colon cancer: A propensity score analysis in a multicenter study. International Journal of Surgery 2014;12:925e930.

10. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal vs. distal colorectum. Gut 2012;61:847–54.

11. Schrag D, Weng S, Brooks G, et al. The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol 2016;34 (suppl; abstr 3505).

12. Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: A systematic review and meta-analysis. JAMA Oncology 2016; (Epub ahead of print).

13. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000−6.

14. Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. British Journal of Cancer 2013;109:1004–12.

15. Bupathi M, Wu C. Biomarkers for immune therapy in colorectal cancer: mismatchrepair deficiency and others. J Gastrointest Oncol 2016;7:713−20.

16. Holch JW, Ricard I, Stinzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer 2016;70:87−98.

17. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; dostupný na:www.ncbi.nlm.nih.gov/pubmed/25713148.

18. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS Wild-Type Metastatic Colorectal Cancer: Retrospective analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2016 Oct 10 (Epub ahead of print).

19. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405. J Clin Oncol 2016;34 (suppl. abstract 3504).

20. Yang J, Du X, Li S, et al. Characteristics of differently located colorectal cancers support proximal and distal classification: A population-based study of 57,847 patients. PLoS ONE 2016; 11:e0167540.

Labels
Surgery Orthopaedics Trauma surgery
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#